TABLE 2

GMCs and 95% CIs of serum specimens from noncases, RICs, cRICs, and pRICS stratified according to timing of serum collection

DaysbNoncasesaRICscRICspRICs
No. of samplesGMCc (95% CI)No. of samplesGMC (95% CI)No. of samplesGMC (95% CI)No. of samplesGMC (95% CI)
0–2121,322 (674–2,593)365,214 (2,884–9,429)5105,714 (43,932–248,686)31,904 (1,573–2,102)
3–442,859 (1,838–4,553)1652,819 (24,570–113,551)4136,888 (68,906–177,788)3157,012 (102,871–193,883)
5–791,838 (741–4,553)21102,163 (68,788–151,732)2197,124 (156,289–248,628)3200,993 (187,189–208,590)
8–4213951 (478–1,895)1557,485 (23,022–143,537)11130,350 (61,547–206,580)255,924 (47,986–65,176)
  • a PRN assay-determined measles neutralizing antibody concentrations identified as outliers were excluded.

  • b Days are after rash onset.

  • c The GMCs were calculated for concentrations of measles neutralizing antibodies measured in mIU/ml.